| 772P - Perioperative atezolizumab with or without the immunomodulatory IMM-101 in patients (pts) with MSI-high (MSI-H) or MMR-deficient (dMMR) stage III colorectal cancer (CRC) ineligible for oxaliplatin-based chemotherapy: The randomised phase II ANTONIO-study (AIO-KRK-0220) |
Karthaus M |
Kasper-Virchow S |
| Ann Oncol 36 (Suppl. 2):532 |
Abstract |
2025 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
ANTONIO |
AIO-KRK-0220 |
| doi.org/10.1016/j.annonc.2025.08.1345 |
|
|
| 2617P - Coaching of renal cell cancer patients on side effects of systemic cancer treatment: Lessons from the phase III PREPARE trial [PREPARE; AIO-NZK-0115/ass; IAG-N] |
Grünwald V |
Ivanyi P |
| Ann Oncol 36 (Suppl. 2):1405-6 |
Abstract |
2025 |
|
Nierenzellkarzinom
|
PREPARE |
AIO-NZK-0115/ass |
| doi.org/10.1016/j.annonc.2025.08.3232 |
|
|
| 2767P - Patients with extensive stage small-cell lung cancer (ES-SCLC) and poor performance status receiving atezolizumab-carboplatin-etoposide (SPACE): A single-arm phase II AIO study (AIO-TRK-0119) |
Sebastian M |
Reck M |
| Ann Oncol 36 (Suppl. 2):1472-3 |
Abstract |
2025 |
|
Thorakale Onkologie
|
SPACE |
AIO-TRK-0119 |
| doi.org/10.1016/j.annonc.2025.08.3378 |
|
|
| Prospective Head and Neck Carcinoma (r/m SCCHN) Clinical Research Platform for molecular and blood-based biomarkers, treatment and outcome (HEAT) |
Pogorzelski M |
Grünwald V |
| Oncol Res Treat 48 (Suppl 2):17 |
Sonstige |
2025 |
|
Kopf-Hals-Tumoren
|
HEAT |
|
| doi.org/10.1159/000548147 |
|
|
| Effectiveness of Maintenance Therapy with Pembrolizumab vs. Pemetrexed and Pembrolizumab in Advanced Non-Small Cell Lung Cancer: Real-world data from the German Prospective CRISP Registry (AIO-TRK-0315) |
Heinzen S |
Sebastian M |
| Oncol Res Treat 48 (Suppl 2):18 |
Sonstige |
2025 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| doi.org/10.1159/000548147 |
|
|
| Institutional Variability in Testing for Actionable Genetic Alterations in Patients with Stage IIIB/C or IV NSCLC: Real-World Data from the Prospective, Multicenter CRISP Registry (AIO-TRK-0315) |
Althoff FC |
Sebastian M |
| Oncol Res Treat 48 (Suppl 2):199 |
Abstract |
2025 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| doi.org/10.1159/000548147 |
|
|
| 2078eP - Combined chemo-immunotherapy versus monoimmunotherapy in advanced high PD-L1-positive NSCLC: Real-world data analyzed with propensity scores technique from the German prospective multicentre registry study (CRISP) |
Metzenmacher M |
|
| Ann Oncol 36 (Suppl. 2):S1092 |
Abstract |
2025 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| doi.org/10.1016/j.annonc.2025.08.2699 |
|
|
| 2011P Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV NSCLC: Real-world data from the prospective, multicenter CRISP registry (AIO-TRK-0315) |
Althoff F |
Sebastian M |
| Ann Oncol 36 (Suppl. 2):1145-6 |
Abstract |
2025 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| doi.org/10.1016/j.annonc.2025.08.2635 |
|
|
| 1841eP - Real-world treatment and outcome of patients with stage II-III NSCLC in Germany from 2018-24 (prospective German registry CRISP, AIO-TRK-0315) |
Eberhardt WEE |
Thomas M |
| Ann Oncol 36 (Suppl. 2):1060 |
Abstract |
2025 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| doi.org/10.1016/j.annonc.2025.08.2464 |
|
|
| 2247P - Growth differentiation factor 15 (GDF-15) in localized, non-metastatic pancreatic cancer treated with multiagent induction chemotherapy: A biomarker analysis from the randomized phase II NEOLAP-1 trial (AIO-PAK-0113) |
Kimmel B |
Kunzmann V |
| Ann Oncol 36 (Suppl. 2): 1245 |
Abstract |
2025 |
|
Pankreaskarzinom
|
NEOLAP |
AIO-PAK-0113 |
| doi.org/10.1016/j.annonc.2025.08.2864 |
|
|
